Abstract
Background: Increased clusterin levels have been reported in brain, cerebrospinal fluid (CSF), and plasma of Alzheimer's disease (AD) patients. Because changes are also observed in mild cognitive impairment (MCI), a possible relationship between clusterin levels and early neurodegenerative changes in AD was suggested. Objectives: To determine whether clusterin concentrations could 1) serve as a diagnostic marker for AD, 2) predict disease progression in MCI, and 3) correlate with AD-biomarkers. Methods: Clusterin levels in CSF and plasma, as well as AD biomarker levels of Aβ
Original language | English |
---|---|
Pages (from-to) | 1103-1110 |
Journal | Journal of Alzheimer's Disease |
Volume | 46 |
Issue number | 4 |
DOIs | |
Publication status | Published - 2015 |